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EVALUATION OF AN IN-HOUSE SPECIFIC IMMUNOGLOBULIN G (IGG) AVIDITY ELISA FOR
DISTINGUISHING RECENT PRIMARY FROM LONG-TERM HUMAN CYTOMEGALOVIRUS (HCMV)
INFECTION
Silmara de SOUZA(1), Sandra H. A. BONON(2), Sandra C. B. COSTA(2) & Cláudio L. ROSSI(1)
SUMMARY
This article describes the standardization and evaluation of an in-house specific IgG avidity ELISA for distinguishing recent
primary from long-term human cytomegalovirus (HCMV) infection. The test was standardized with the commercial kit ETI-CYTOK
G Plus (Sorin Biomedica, Italy) using 8 M urea in phosphate-buffered saline to dissociate low-avidity antibodies after the antigen-
antibody interaction. The performance of the in-house assay was compared to that of the commercial automated VIDAS CMV IgG
avidity test (bioMérieux, France). Forty-nine sera, 24 from patients with a recent primary HCMV infection and 25 from patients with
a long-term HCMV infection and a sustained persistence of specific IgM antibodies, were tested. Similar results were obtained with
the two avidity methods. All 24 sera from patients with recently acquired infection had avidity indices compatible with acute HCMV
infection by the VIDAS method, whereas with the in-house method, one serum sample had an equivocal result. In the 25 sera from
patients with long-term infection, identical results were obtained with the two methods, with only one serum sample having an
incompatible value. These findings suggest that our in-house avidity test could be a potentially useful tool for the immunodiagnosis
of HCMV infection.
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INTRODUCTION
Human cytomegalovirus (HCMV) is a member of the herpes family
of viruses, which also includes herpes simplex virus, varicella-zoster
virus, human herpes virus 6 and Epstein-Barr virus. Although HCMV
has a world-wide distribution, infection with HCMV is more common
in developing countries, particularly in areas with poor socioeconomic
conditions5,22. As with other herpesvirus infections, primary HCMV
infection is followed by chronic infection or viral latency from which
the virus may be reactivated21. Primary infection or reactivation of HCMV
is usually either subclinical or self-limiting in immunocompetent
persons5,12,18. However, in immunocompromised hosts such as organ
transplant recipients, patients with cancer and individuals infected with
human immunodeficiency virus (HIV), or in congenital infections, a
significantly adverse clinical course and outcome is often seen18-22.
HCMV is the most common agent of viral intrauterine infection and
affects 0.5-2.5% of all live births in different parts of the world1,10,19,20. In
pregnant women, distinguishing the primary from non-primary HCMV
infection is important, since the former is much more deleterious to the
fetus than the latter22. This is also true for immunocompromised patients,
in whom primary infections are often accompanied by symptoms whereas
non-primary infection is usually asymptomatic14.
The diagnosis of recently acquired HCMV infection is usually based
on the detection of specific immunoglobulin (Ig) M antibodies,
seroconversion or a significant increase in specific IgG antibody
concentrations. Since seroconversion, the most dependable serological
marker, and a rise in IgG titres are seldom demonstrable, the detection
of HCMV-specific IgM antibodies has been the most frequently used
serological procedure for diagnosing acute infection. However, in some
persons, IgM may be detected for many months following primary
infection and may also be produced following reinfection or
reactivation11,13,15,17,22. Moreover, false-positive HCMV results may occur
with other herpesviruses and with some autoimmune disorders6,13,17.
Based on the observation that antibody avidity gradually increases
after exposure to an immunogen8,23, several reports have shown that the
avidity of IgG antibodies can be used as a marker for distinguishing
recent primary from long-term infections, including HCMV infec-
tions2-4,7,9,16.
In Brazil, commercial assays for evaluating the avidity of HCMV-
specific IgG are expensive and are not readily available. The aim of this
study was to standardize an economical in-house HCMV-enzyme-linked
immunosorbent assay (ELISA) avidity test for routine use. To validate
this in-house assay, its performance was compared with that of the
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commercial automated VIDAS CMV IgG avidity assay (bioMérieux,
France), using well-characterized sera from patients with recent primary
and long-term HCMV infections.
MATERIALS AND METHODS
Avidity tests: The in-house avidity assay was standardized using a
commercial ELISA kit for detecting specific IgG antibodies (ETI-
CYTOK-G Plus, Sorin Biomedica, Italy) modified to incorporate an
elution step with urea to remove low-avidity antibodies from HCMV
antigen. For the assay, 100 µl of each serum diluted 1:101 were added to
wells of polystyrene plates coated with HCMV antigen. All serum
samples were run twice in duplicate. After incubation for 1 h at 37 oC,
the wells were washed four times with 0.15 M phosphate-buffered saline,
pH 7.2 (PBS), and 100 µl of 8 M urea in PBS were added to two wells,
whereas 100 µl of PBS were added to the other two wells. After incubation
for 5 min at room temperature and washing two times with PBS, 100 µl
of the optimal dilution of the conjugate in PBS were added to the wells.
After a further 1 h incubation at 37 oC and washing four times with PBS,
100 µl of the substrate system (tetramethylbenzidine/hydrogen peroxide)
were added to the wells. Thirty minutes after the addition of substrate,
100 µl of 4 N H2SO4 were added to each well to stop the reaction and the
resulting absorbances were measured in an ELISA reader (Spectra SLT,
SLT Instruments, Austria) at 450 and 405 nm, with 620 nm used as the
reference wavelength. The results obtained at 405 nm were used only
when the reactions read at 450 nm had an O.D. higher than the linear
range of the ELISA reader.
The avidity index was calculated as the mean absorbance of reactions
in which the immune complexes were exposed to urea divided by the
mean absorbance of reactions in which the immune complexes were not
exposed to urea, expressed as a percentage. The run-to-run variation
was determined by assaying an HCMV positive serum pool on five
alternate days. On each day, the serum pool was tested in duplicate and
the mean absorbance determined. The interassay CV was determined
from the mean absorbance obtained in the five assays. The cut-off value
was calculated using a modification of the J index24. The J index was
calculated for avidity indices ranging from 30% to 70% at 5% intervals,
using the formula: J = (a/b) + (c/d) - 1, where a is the number of sera
with a compatible avidity index in the group of sera from patients with
a recent infection, b is the total number of sera from patients with a
recent infection, c is the number of sera with a compatible avidity index
in the group of sera from patients with a long-term infection and d is the
total number of sera from patients with a long-term infection. Low and
high avidity indices were defined based on the cut-off value and the
interassay CV.
The automated VIDAS system (bioMérieux, France) combines a two-
step enzyme immunoassay sandwich method with a final fluorescent
detection (ELFA). In the VIDAS CMV IgG assay, the results are
expressed as a relative fluorescence value (RFV) and, in the absence of
international units, as VIDAS arbitrary units (AU per milliliter). For the
determination of avidity, two strips containing the reagents are used. In
one strip a buffer containing 6 M urea is used to elute low-avidity
antibodies. In the other strip, which serves as the reference test, the buffer
with urea is replaced by a wash buffer without urea. The avidity index is
determined by calculating the ratio of the RFV result obtained for the
sample with the strip containing urea relative to the RFV result obtained
for the sample with the strip without urea. According to the manufacturer,
an index ≥ 0.80 excludes a recent primary infection of less than three
months whereas an index < 0.8 does not.
Patients and serum samples: The avidity tests were evaluated by
testing sera from 24 patients with a recent primary HCMV infection and
sera from 25 patients with a long-term HCMV infection and a sustained
persistence (> 1 year) of specific IgM antibodies detected by ELISA.
Serum HCMV-IgM and HCMV-IgG antibodies were determined using
the automated VIDAS system (bioMérieux, France). Patients were
diagnosed as having a recent HCMV infection based on serodiagnostic
criteria: seroconversion (appearance of specific IgM and IgG antibodies
in a previously seronegative patient) and/or detection of significant levels
of specific IgM antibodies. All 24 patients in this group had clinical
manifestations compatible with acute HCMV infection and the sera were
collected in the first three months after the onset of the symptoms. All
25 patients with long-term HCMV infection had a well-documented
history of pre-existing HCMV infection and the sera were collected no
less than one year after the beginning of infection. Most (n = 20) of the
sera in this latter group were from transplant recipients (13 renal, three
liver, and four bone marrow).
RESULTS
Preliminary experiments with the in-house IgG avidity assay using
varying concentrations of urea and different treatment times showed
that a 5 min incubation step with 8 M urea was the best combination for
discriminating antibody avidities in patients with recent primary and
long-term HCMV infections. The IgG avidity indices obtained with the
in-house and VIDAS CMV methods for the sera from patients with recent
primary and long-term HCMV infections are shown in Fig. 1.
The in-house avidity indices for the 24 acute-phase serum samples
ranged from 10.3% to 52.1% (mean index = 29.5%) whereas for the 25
serum samples from patients with a long-term infection, the indices
ranged from 44.4% to 96.4% (mean index = 78.4%). The highest J index
was obtained with an avidity index of 55%. Considering the interassay
CV (4.9%), avidity indices < 50% and > 60% were considered indicative
of recent and long-term HCMV infection, respectively. Based on this
criterion 23 (95.8%) of 24 sera from patients with a recent primary HCMV
infection and 24 (96%) of 25 sera from patients with a long-term infection
had in-house avidity indices compatible with the stage of infection.
The VIDAS-CMV avidity indices for the 24 acute-phase sera ranged
from 0.06 to 0.67 (mean index = 0.25) whereas for the 25 serum samples
from patients with a long-term infection, the indices ranged from 0.71
to 1 (mean index = 0.93). According to the manufacturer, an index ≥ 0.80
excludes a recent primary infection of less than 3 months whereas an
index < 0.8 does not.
Based on the criteria for interpreting avidity assays, divergent results
were found in one acute-phase serum sample (avidity index = 52.1%)
with the in-house method and in one long-term serum sample with the
in-house (avidity index = 44.4%) and VIDAS (avidity index = 0.71)
methods. The long-term infection sample was taken 15 months after
seroconversion from a patient who acquired primary HCMV infection
after a renal transplant.
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DISCUSSION
HCMV is a serious, life-threatening opportunistic pathogen in
immunocompromised persons, and is one of the principal causes of
congenital malformations and neurological defects in infected neonates19-22.
The diagnosis of a recently acquired HCMV infection is usually
based on the detection of specific IgM antibodies, seroconversion, or a
four-fold or greater rise in the titre of HCMV-specific IgG antibodies.
Since seroconversion and a rise in IgG titres are seldom demonstrable,
the detection of HCMV-specific IgM antibodies has been the most
frequently used serological marker for diagnosing acute infection.
However, the use of tests with a low specificity and the persistence, in
some patients, of specific IgM antibodies for a long time have led to the
misdiagnosis of acute HCMV infection and unnecessary concern,
especially with respect to pregnant women and immunocompromised
patients. The determination of antibody avidity represents an important
additional serological marker in the immunodiagnosis of several
infections because low - and high-avidity antibodies occur predominantly
in recent and long-term infections, respectively. The use of IgG avidity
assays to confirm or exclude acute HCMV infection in cases of an IgM-
positive result strengthens the serological diagnosis and could prevent
unnecessary invasive procedures in numerous cases.
In this work, we standardized and evaluated an in-house specific IgG
avidity ELISA for distinguishing recent primary from long-term HCMV
infection. The performance of the in-house assay was compared with that
of a commercial automated VIDAS CMV IgG avidity test. Forty-nine
sera, 24 from patients with a recent primary HCMV infection and 25 from
patients with a long-term HCMV infection with a sustained persistence of
specific IgM antibodies, were tested. Similar results were obtained with
the two avidity methods. All sera from the 24 patients with recently acquired
infection had avidity indices compatible with acute HCMV infection by
the VIDAS method, whereas with the in-house method, one serum sample
had an equivocal result. In the 25 sera from patients with long-term
infection, identical results were obtained with the two methods, with only
one serum sample having an incompatible value. The avidity indices used
to discriminate between low (< 50%) and high (> 60%) IgG avidity in our
in-house avidity assay were similar to values published by other
investigators. BODÉUS et al.4, who used an avidity test with 8 M urea as
the dissociating agent to screen serum samples from patients with a recent
primary or long-term HCMV infection, showed that an avidity index < 50%
corresponded to a recent primary infection, whereas an avidity index > 65%
was highly suggestive of a past infection. GRANGEOT-KEROS et al.9
also used an avidity test with 8 M urea as the dissociating agent to screen
serum samples from pregnant women in different stages of HCMV
infection. These authors showed that sera from women with a past or
secondary HCMV infection had an avidity index > 60%, whereas most of
the sera from women with HCMV primary infection had avidity index
< 50%. In a similar study, using 6 M urea as dissociating agent, EGGERS
et al.7 defined avidity indices of < 40% and > 60% as indicative of acute
primary and past HCMV infection, respectively. In a study of sera from
pregnant women who had recently seroconverted following primary
HCMV infection (within four months of the last negative sample) and of
sera from individuals with long-term HCMV infection, PRINCE &
LEBER16 showed that 99% of the acute-phase serum samples had avidity
indices < 50%, whereas 96% of serum samples from persons with past
infection had avidity indices > 60%.
Variations in the ranges for low- and high-avidity antibodies are
expected and are probably related to several factors, including patient
heterogeneity, immune status at the time of blood collection, time of
Fig. 1 - Avidity index results in sera from patients with HCMV infection obtained with the in-house (a) and VIDAS (b) methods. A = recent primary infection (n = 24); B = long-term infection
(n = 25). RFVu = relative fluorescence value in the presence of urea; RFVa = relative fluorescence value in the absence of urea. In the in-house test, avidity indices < 50% and > 60% were
considered compatible with recent primary and long-term HCMV infections, respectively. In the VIDAS test, according to the manufacturer, an index ≥ 0.8 excludes a recent primary infection
of less than 3 months whereas an index < 0.8 does not.
326
SOUZA, S.; BONON, S.H.A.; COSTA, S.C.B. & ROSSI, C.L. - Evaluation of an in-house specific immunoglobulin G (IgG) avidity ELISA for distinguishing recent primary from long-term
human cytomegalovirus (HCMV) infection. Rev. Inst. Med. trop. S. Paulo, 45(6):323-326, 2003.
blood sampling relative to the onset of infection, assay technique, antigen
preparation, type and concentration of hydrogen bond-disrupting agent,
and the method of calculating antibody avidity.
The results of this study suggest that our in-house avidity test may
be a potentially useful tool for the immunodiagnosis of HCMV infections.
RESUMO
Avaliação de um teste de avidez imunoenzimático para o
citomegalovírus humano (ELISA-HCMV) para distinguir a
infecção primária recente da infecção de longa duração
Este artigo descreve a padronização e avaliação de um teste de avidez
imunoenzimático para o citomegalovírus humano (ELISA-HCMV) para
distinguir a infecção primária recente da infecção de longa duração. O
teste foi padronizado com o kit comercial ETI-CYTOK G Plus (Sorin
Biomedica, Itália), utilizando uréia 8 M para a dissociação dos anticorpos
de baixa avidez. A performance do teste ELISA-HCMV foi comparada
com a do teste de avidez comercial automatizado VIDAS CMV IgG
(bioMérieux, França), utilizando 24 soros de pacientes com infecção
primária recente e 25 soros de pacientes com infecção de longa duração
apresentando persistência de anticorpos específicos IgM. Resultados
similares foram obtidos com os dois métodos de avidez. Todos os 24
soros de pacientes com infecção recentemente adquirida apresentaram
índices de avidez compatíveis com infecção aguda pelo HCMV utilizando
o teste VIDAS CMV IgG, enquanto que um dos soros apresentou
resultado duvidoso no teste ELISA-HCMV. Os 25 soros de pacientes
com infecção de longa duração apresentaram resultados idênticos com
os dois métodos, com apenas um dos soros apresentando um valor não
compatível. Estes resultados sugerem que o teste de avidez descrito pode
ser potencialmente útil para o imunodiagnóstico da infecção pelo HCMV.
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